XTL Acquires Stake In iviGene

XTL Biopharmaceuticals Ltd has acquired a stake in U.S.-based iviGene Corporation. The acquisition gives XTL access to iviGene‘s proprietary IVIAT technology for identifying novel drug targets for treating a broad range of infectious diseases. The technology is expected to enable XTL to develop both novel human monoclonal antibody and small molecule drugs for antiviral, antibacterial Read more about XTL Acquires Stake In iviGene[…]

Epimmune Licenses Gene Delivery Technologies

Epimmune Inc. has licensed Valentis, Inc.’s proprietary PINC gene delivery technology for Epimmune’s preventive and therapeutic DNA vaccines in development against the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV). Valentis has granted Epimmune a non-exclusive license to certain patented and non-patented technology for use in developing DNA vaccines against HIV and HCV Read more about Epimmune Licenses Gene Delivery Technologies[…]

Corixa Receives Grant To Develop Tuberculosis Vaccine

Corixa Corporation has been awarded a $2.3 million Challenge Grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a new candidate vaccine for the treatment of tuberculosis. As a result, Corixa will conduct preclinical and clinical testing of a new candidate vaccine produced using M. tuberculosis proteins, combined with formulations developed Read more about Corixa Receives Grant To Develop Tuberculosis Vaccine[…]

vaccine technology

Epimmune Receives Patent For Vaccine Technology

Epimmune Inc. announced that the U.S. Patent and Trademark Office has issued the Company a patent relating to the Company’s core vaccine technology. The patent is U.S. Patent Number 6,037,135 entitled “Methods of Making HLA Binding Peptides and Their Uses,” and it includes claims covering methods for using any genomic or protein sequence to discover Read more about Epimmune Receives Patent For Vaccine Technology[…]


ArQule And Genome Therapeutics Sign Anti-infective Agreement

ArQule, Inc. and Genome Therapeutics have announced a new drug discovery collaboration uniting their key strengths in the genomics and chemistry fields. ArQule will use their new Parallel Track Drug Discovery program to screen and optimise compounds against an expanded number of proprietary validated anti-infective targets which Genome Therapeutics has derived from its PathoGenome Database. Read more about ArQule And Genome Therapeutics Sign Anti-infective Agreement[…]

Prodigene Announces Milestone In Nih Collaboration

ProdiGene, Inc. announced at the Keystone Symposia, that it successfully expressed a sub unit vaccine in maize that is expected to produce an immune response to simian immunodeficiency virus (SIV), the primate equivalent to HIV.The research is funded by an Innovation Grant program from the NIH Institute of Allergy and Infectious Disease’s Office of AIDS Read more about Prodigene Announces Milestone In Nih Collaboration[…]

iomai corporation

Berna And Iomai Announce Collaboration

Berna Biotech Ltd. and Iomai Corporation have announced a collaboration for the development of vaccines for administration using a skin patch. The collaboration will pool Berna’s expertise in the development of vaccines and novel adjuvants with Iomai’s expertise in skin delivery using its proprietary patch technology. Needle-free delivery has become a global priority because of Read more about Berna And Iomai Announce Collaboration[…]

RiboTargets LTD

RiboTargets And Sun Microsystems Collaborate

RiboTargets and Sun Microsystems Inc. have entered into a collaboration using high-powered computing methods to discover a novel class of antibiotic. In the collaboration, Sun committed a 200 processor SUN TCF (Technical Compute Farm) on which RiboTargets has been running its unique virtual screening software RiboDock. The software is designed to screen huge numbers of Read more about RiboTargets And Sun Microsystems Collaborate[…]


Bioenvision Completes Acquisition Of Pathagon

Bioenvision has closed its acquisition of Pathagon, a privately held company focused on the development of novel anti-infective products and technologies. With the acquisition, Bioenvision adds to its portfolio the rights to two FDA approved and marketed anti-infective technologies, OLIGON (TM) and methylene blue. Dr. Chris Wood MD, Bioenvision’s President & CEO, commented, “we are Read more about Bioenvision Completes Acquisition Of Pathagon[…]

AVANT Immunotherapeutics

Avant Licenses Vaccine Technology

AVANT Immunotherapeutics, Inc. has signed a license agreement with DynPort Vaccine Company LLC (DVC) for exclusive rights to use certain components of AVANT’s vaccine technology. DVC, a private company, is chartered with providing an integrated approach for the advanced development of specific vaccines and other products to protect against the threat of biological warfare agents. Read more about Avant Licenses Vaccine Technology[…]

Obtain Dragon Pharma Online

1-Test Cyp 200

Injectable Anabolic Steroid
Basal Ingredient: Dihydroboldenone Cypionate
Manufacturer: Dragon Pharmaceutical
Package: 1 X 10 mL vial (200 mg/mL)

Turanabol - Discount Price

Administration: Oral
Primary Substance: Chlorodehydromethyltestosterone
Branded by: Dragon Pharmaceuticals
Pack: 30 x 100 pills (10 mg/pill)
Price: 30 x $55.00

EQ 200 / Test E 200

Injectable Anabolic Steroid
Prime Chemical Name: Boldenone Undecylenate, Testosterone Enanthate
Manufacturer: Dragon Pharma Labs
Package: 1 X 10 mL vial (400 mg/mL)

TriTren 150 - Bulk Price

Administration: Injection
Primary Substance: Tri Trenbolone
Produced by: Dragon Pharma Labs
Amount: 10 x 10 mL vial (150 mg/mL)
Price: 10 x $72.00

Parabolan 100 - Cheap Price

Administration: Injection
Primary Component: Trenbolone Hexahydrobenzylcarbonate
Producer: Dragon Pharma LLC
Pack: 20 x 10 mL vial (100 mg/mL)
Price: 20 x $55.00

Trenbolone 100 [10 Vials]

Injectable Steroid for Muscle Growth
Active Chemical Name: Trenbolone Acetate
Manufacturer: Dragon Pharma LLC
10 Vials [10 mL per Vial (100 mg/ml)]
Price: 10 x $60.00 = $600.00 in Total


Oral Steroid for Muscle Growth
Base Substance: Methandrostenolone
Producer: Dragon Pharmaceuticals
100 tablets (20 mg/pill)

1-Test Cyp 200

Injectable Steroid for Muscle Growth
Prime Ingredient: Dihydroboldenone Cypionate
Made by: Dragon Pharma
10 mL Sterile Multi-dose Vial (200 mg/mL)


Basal Component: Tamoxifen Citrate
Producer: Dragon Pharma Labs
Unit: 100 tabs (50 mg/pill)

Sustanon 350 [10 Vials]

Injectable Steroid for Muscle Growth
Mix of:
- 42mg Testosterone Propionate
- 84mg Testosterone Isocaproate
- 84mg Testosterone PhenylPropionate
- 140mg Testosterone Decanoate
Manufacturer: Dragon Pharmaceuticals
10 Vials [10 mL per Vial (350 mg/ml)]
Price: 10 x $45.00 = $450.00 in Total

Trenbolone 200

Injectable Steroid for Muscle Growth
Principal Chemical Name: Trenbolone Enanthate
Producer: Dragon Pharma Labs
10 mL Sterile Multi-dose Vial (200 mg/mL)


Oral Steroid for Muscle Growth
Active Constituent: Oxandrolone
Producer: Dragon Pharma
100 tabs (50 mg/pill)